Resp Flashcards
normal values of FEV1, FVC and FEV1/FVC?
FEV1 - <80% abnormal
FVC <80 abnormal
FEV1/FVC <0.7 = airway obstruction and normal FEV1/FVC but low FVC = airway restriction
type 1 and type 2 respiratory failure?
type 1; hypoxia and normal or low co2 -> typically caused by PE
type 2; hypoxia and hypercapnia
signs of hypercapnoea?
- Bounding pulse
- Flapping tremor
- Confusion
- Drowsiness
- Reduced consciousness
obstructive lung disease?
- FEV1/FVC below 0.7
- FEV1 lower than FVC
- ASTHMA and COPD
restrictive lung disease?
• FEV1/FVC above 0.7 • FVC & FEV1 below 80% predicted value • Due to restriction, lung volumes are small and most of breath is out in first second • Interstitial lung disease: - FIBROSING ALVEOLITIS - SARCOID
transfer co-efficent?
• Measure of ability of oxygen to diffuse across the alveolar membrane
• Can calculate by inspiring a small amount of carbon monoxide (not too
much since can kill) then hold breath for 10 seconds at total lung
capacity (TLC) then the gas transferred is measured
low in; COPD and anaemia
high in; pulmonary haemorrhage
COPD
• A disease state characterised by airflow limitation that is not fully reversible
• The airflow limitation is usually both progressive and associated with an abnormal
inflammatory response of the lungs to noxious particles or gases
epidemiology of COPD?
- middle age
aetiology of COPD?
- CIGARETTE SMOKING is the MAJOR cause of COPD and is related to the
daily average of cigarettes smoked and years spent smoking - Chronic exposure to:
• Pollutants at work (mining, building and chemical industries)
• Outdoor air pollution
• Inhalation of smoke from biomass fuels used in heating and cooking in
poorly ventilated areas
• These factors also play a role, particularly in developing countries - Alpha-1 antitrypsin deficiency:
• Causes early onset COPD (due to proteolytic lung damage)
• A rare cause of cirrhosis (due to accumulation of the abnormal protein
in the liver)
• Mutations in the alpha-1 antitrypsin gene on chromosome 14 lead to
reduced hepatic production of alpha-1 antitrypsin which normally
inhibits the proteolytic enzyme - neutrophil elastase
pathophysiology of COPD?
- There is increased numbers of mucus-secreting goblet cells in COPD within
the bronchial mucosa, especially in the larger bronchi - In more advanced cases the bronchi become overtly inflamed and pus is seen
in the lumen - causes chronic bronchitis and emphysema
- The combination of emphysema (loss of elastic recoil of the lung with collapse
of small airways during expiration) and chronic bronchitis (airway narrowing)
results in severe airflow limitation - V/Q (ventilation perfusion) mismatch is partly due to damage and mucus
plugging of smaller airways from the chronic inflammation and partly due to
rapid closure of smaller airways in expiration owing to the loss of elastic
support - this mismatch leads to a fall in PaO2 and increased work or
respiration
chronic bronchitis - COPD physiology
• There is airway narrowing and hence airflow
limitation as a result of hypertrophy and
hyperplasia of mucus secreting glands of
the bronchial tree, bronchial wall
inflammation and mucosal oedema
• Microscopically there is infiltration of the
walls of the bronchi and bronchioles with
acute and chronic inflammatory cells
• The epithelial layer may become ulcerated and, with time, squamous
epithelium replaces the columnar cells (squamous metaplasia) when
the ulcer heals
• The inflammation is followed by scarring and thickening of the walls,
which narrows the small airways
• The small airways are particularly affected early in the disease, initially
without the development of any significant breathlessness
• The initial inflammation is reversible and accounts for the improvement
in airway function if smoking is stopped early
• In the later stages, the inflammation continues, even if smoking is
stopped
• Patients chronic bronchitis are referred to as blue bloaters
emphysema - COPD pathology
• Defined as dilatation and destruction of the lung tissue distal to the
terminal bronchioles
• Results in loss of elastic recoil, which normally keeps the airways open
during expiration
• Leads to expiratory airflow limitation and air trapping
• Premature closure of airways limits expiratory flow while the loss of
alveoli decreases capacity for gas transfer
• Patients with emphysema are referred to as the pink puffers
types of emphysema
- Centri-acinar emphysema:
• Distension and damage of lung tissue is concentrated around
the respiratory bronchioles, whilst the more distal alveolar
ducts and alveoli tend to be well preserved
• Extremely common - Pan-acinar emphysema:
• Less common
• Distension and destruction affect the whole acinus and in
severe cases the lung is just a collection of bullae
• Associated with alpha-1 antitrypsin deficiency - Irregular emphysema:
• Scarring and damage that affects the lung parenchyma
patchily, independent of acinar structure
pathogenesis of cigarette smoking?
- Causes mucus gland hypertrophy in the larger airways and leads
to an increase in neutrophils, macrophages and lymphocytes in
the airways and walls of the bronchi and bronchioles - These cells release inflammatory mediators (elastases, proteases,
IL-1,-8 & TNF-alpha) that attracts inflammatory cells (further
amplify the process), induce structural changes and break down
connective tissue (protease-antiprotease imbalance) in the lung
resulting in emphysema - Inactivates the major protease inhibitor alpha-1 antitrypsin
clinical presentation of COPD?
- Characteristic symptoms are productive cough with white or clear sputum,
wheeze and breathlessness, usually following many years of a smokers
cough - Systemic effects include:
• Hypertension
• Osteoporosis
• Depression
• Weight loss
• Reduced muscle mass with general weakness - pulmonary hypertension due to hypoxic kidney
investigations of COPD?
- Based on a history of breathlessness and sputum production in a chronic
smoker - In the absence of a history of cigarette smoking then asthma is a more likely
explanation, unless there is a family history suggesting alpha-1 antitrypsin
deficiency - LUNG FUNCTION TEST -> fev1/fvc <0.7
- CXR -> maybe normal or shower hyper inflated lungs
- ABG
COPD treatment?
- SMOKING CESSATION IS MOST USEFUL,
- BRONCHODILATOR - LABA eg, salmterol or SABA eg, salutomal
- LAMA - eg, tiotropium bromide
- corticosteroid eg, prednisolone
asthma? epidemiology
- Commonly starts in childhood between the ages 3-5 years and may either
worsen or improve during adolescence - Peak prevalence between 5-15 years
3 key characteristics of asthma?
- Airflow limitation - usually reversible spontaneously or with treatment
- Airway hyper responsiveness (ADAM33)
• Bronchial inflammation with T lymphocytes, mast cells, eosinophils
with associated plasma exudation, oedema, smooth muscle hypertrophy,
mucus plugging and epithelial damage
types of asthma?
• Allergic/eosinophilic asthma (70%):
- Allergens (e.g. fungal allergens and pets etc.) & atopy (readily develop IgE)
• Non-allergic/non-eosinophilic (30%):
- Exercise, cold air & stress
- Smoking & non smoking associated
- Obesity associated
PATHOPHYSIOLOGY OF ASTHMA?
- Primary abnormality in asthma is narrowing of the airway which is due to
smooth muscle contraction, thickening of the airway wall by cellular
infiltration and inflammation and the presence of secretions within the airway
lumen - Inflammation: MAST CELLS bind to IgE and will respond if allergen binds to IgE; it releases histamine (bronchconstriction), tryptase, prostaglandin 2, cytokines
- Eosinophils release proteins and peroxidase which are toxic to epithelial cells
first bronchoconstriction then inflammation due to immune cell infiltration and then worsening inflammation due to eosinophil
remodelling - hypertrophy and hyperplasia causing excess airway narrowing
clinical presentation of asthma
- Intermittent dysponea (difficulty breathing)
- Wheeze
- Cough (especially nocturnal) - frequent symptom in children
- Sputum
- Symptoms worse at night
life threatening asthma attack?
- Silent chest
- Confusion & exhaustion
- Cyanosis (PaO2 less than 8kPa)
- Bradycardia
- PEFR less than 33%
immediate management for asthma attack
• Oxygen therapy to maintain O2 sat (94%-98%)
• Nebulised 5mg salbutamol (+ ipratropium if life threatening) - repeat/IV
infusion
• Prednisolone (with or without hydrocortisone IV)
• Take arterial blood gases and repeat within 2 hours if severe attack or
patient deteriorating
• Chest X-ray if fails to respond to treatment
• Check PEFR within 15-30 mins/regularly
• Oximetry to ensure SaO2 is greater than 92%